collection
https://read.qxmd.com/read/38307604/management-of-venous-thromboembolism-in-patients-with-active-cancer
#1
REVIEW
Heloni M Dave, Alok A Khorana
Venous thromboembolism (VTE) is a major health burden in patients with cancer, causing morbidity, emergency room visits, hospitalizations, and death. Treatment is challenging, as it is necessary to balance the risk of recurrent thrombosis and bleeding associated with anticoagulants. Treatment paradigms are shifting from low-molecular-weight heparin monotherapy. Multiple recent randomized controlled trials have demonstrated the safety and efficacy of direct oral anticoagulants in this setting. Current studies are evaluating factor XI inhibitors as potential treatments for cancer-associated VTE...
February 2, 2024: Cleveland Clinic Journal of Medicine
https://read.qxmd.com/read/38307607/what-are-the-management-considerations-for-venous-thromboembolic-events-in-patients-with-cirrhosis
#2
JOURNAL ARTICLE
Marie M Plante, Emily B Wolf, Razvan M Chirila
No abstract text is available yet for this article.
February 2, 2024: Cleveland Clinic Journal of Medicine
https://read.qxmd.com/read/38288941/practical-guidance-for-direct-oral-anticoagulant-use-in-the-treatment-of-venous-thromboembolism-in-primary-and-metastatic-brain-tumor-patients
#3
REVIEW
Surabhi Ranjan, Denise Leung, Ashley P Ghiaseddin, Jennie W Taylor, Mina Lobbous, Andrew Dhawan, Joshua A Budhu, Elizabeth Coffee, Kaitlyn Melnick, Sajeel A Chowdhary, Christine Lu-Emerson, Sylvia C Kurz, Joy E Burke, Keng Lam, Mallika P Patel, Erin M Dunbar, Nimish A Mohile, Katherine B Peters
Management of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors (BT) is challenging because of the risk of intracranial hemorrhage (ICH). There are no prospective clinical trials evaluating safety and efficacy of direct oral anticoagulants (DOACs), specifically in patients with BT, but they are widely used for VTE in this population. A group of neuro-oncology experts convened to provide practical clinical guidance for the off-label use of DOACs in treating VTE in patients with BT...
January 30, 2024: Cancer
https://read.qxmd.com/read/38260965/compression-therapy-in-the-treatment-of-acute-deep-venous-thrombosis-of-the-lower-limb-and-for-the-prevention-of-post-thrombotic-syndrome%C3%A2-a-review-based-on-a-structured-literature-search
#4
REVIEW
Dorothea Thieme, Birgit Linnemann, Katja Mühlberg, Thomas Noppeney, Maria Kreutz, Marcus Thieme
BACKGROUND: After an acute deep venous thrombosis (DVT) of the lower limb, 20% to 65% of patients develop post-thrombotic syndrome (PTS). In this review, we address the efficacy of compression therapy in the treatment of acute DVT of the lower limb, and for the prevention of PTS. METHODS: 12 randomized controlled trials (RCTs) and one meta-analysis, with a total of 3759 patients, were identified in a structured literature search. RESULTS: Two RCTs showed that adding compression therapy to drug treatment in the first 9 days of the acute phase of lower limb DVT led to more rapid pain relief (p<0...
March 22, 2024: Deutsches Ärzteblatt International
https://read.qxmd.com/read/38176425/developmental-or-procedural-vena-cava-interruption-and-venous-thromboembolism-a-review
#5
JOURNAL ARTICLE
Behnood Bikdeli, Parham Sadeghipour, Junyang Lou, Antoine Bejjani, Candrika D Khairani, Sina Rashedi, Robert Lookstein, Alexandra Lansky, Suresh Vedantham, Piotr Sobieszczyk, Carlos Mena-Hurtado, Ayaz Aghayev, Peter Henke, Ghazaleh Mehdipoor, Antonella Tufano, Saurav Chatterjee, Saskia Middeldorp, Suman Wasan, Riyaz Bashir, Irene M Lang, Mehdi H Shishehbor, Marie Gerhard-Herman, Jay Giri, Matthew T Menard, Sahil A Parikh, Lucia Mazzolai, Lisa Moores, Manuel Monreal, David Jimenez, Samuel Z Goldhaber, Harlan M Krumholz, Gregory Piazza
The inferior vena cava (IVC) and superior vena cava are the main conduits of the systemic venous circulation into the right atrium. Developmental or procedural interruptions of vena cava might predispose to stasis and deep vein thrombosis (DVT) distal to the anomaly and may impact the subsequent rate of pulmonary embolism (PE). This study aimed to review the various etiologies of developmental or procedural vena cava interruption and their impact on venous thromboembolism. A systematic search was performed in PubMed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines per each clinical question...
January 4, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38145574/how-i-diagnose-and-treat-antiphospholipid-syndrome-in-pregnancy
#6
JOURNAL ARTICLE
D Ware Branch, Ming Y Lim
Antiphospholipid syndrome (APS) is a rare autoimmune disease characterized by arterial, venous, or microvascular thrombosis, pregnancy morbidities, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies. These antibodies bind cellular phospholipids and phospholipid-protein complexes resulting in cellular activation and inflammation that lead to the clinical features of APS. Our evolving understanding of APS has resulted in more specific classification criteria. Patients meeting these criteria should be treated during pregnancy according to current guidelines...
February 29, 2024: Blood
https://read.qxmd.com/read/38112771/high-and-intermediate-risk-pulmonary-embolism-in-the-icu
#7
REVIEW
Scott J Millington, Nadia Aissaoui, Emma Bowcock, Daniel Brodie, Karine E A Burns, Ghislaine Douflé, François Haddad, Tim Lahm, Gregory Piazza, Olivier Sanchez, Laurent Savale, Antoine Vieillard-Baron
Pulmonary embolism (PE) is a common and important medical emergency, encountered by clinicians across all acute care specialties. PE is a relatively uncommon cause of direct admission to the intensive care unit (ICU), but these patients are at high risk of death. More commonly, patients admitted to ICU develop PE as a complication of an unrelated acute illness. This paper reviews the epidemiology, diagnosis, risk stratification, and particularly the management of PE from a critical care perspective. Issues around prevention, anticoagulation, fibrinolysis, catheter-based techniques, surgical embolectomy, and extracorporeal support are discussed...
December 19, 2023: Intensive Care Medicine
https://read.qxmd.com/read/38133539/pulmonary-embolism-a-practical-approach-to-update-risk-stratification-and-treatment-decisions-based-on-the-guidelines
#8
REVIEW
María Barca-Hernando, Luis Jara-Palomares
INTRODUCTION: Pulmonary embolism (PE) is a prevalent condition with a substantial morbi-mortality worldwide. Proper risk stratification of PE is essential for identifying the most suitable therapeutic strategy and the optimal care setting for the patient. This process entails evaluating various factors, including symptoms, comorbidities, and right heart dysfunction. AREAS COVERED: This review assesses the tools and methods utilized to identify and stratify individuals based on the probability of developing deterioration or death related to PE...
December 22, 2023: Expert Review of Respiratory Medicine
https://read.qxmd.com/read/38105123/the-prophylaxis-of-venous-thromboembolism-in-medical-patients-if-you-do-it-do-it-right
#9
JOURNAL ARTICLE
Claudio Cimminiello
No abstract text is available yet for this article.
December 16, 2023: European Journal of Internal Medicine
https://read.qxmd.com/read/38090315/characteristics-of-pulmonary-infarction-in-patients-with-acute-pulmonary-embolism-in-china-a-single-center-retrospective-observational-study
#10
JOURNAL ARTICLE
Yuan Yuan, Huan-Yong Wang, Zhen-Chuan Xing, Zi-Liang Hou, Jin-Xiang Wang, Shuai Zhang
BACKGROUND: Pulmonary infarction (PI) is an uncommon complication of pulmonary embolism (PE). The risk factors of PI are still relatively unclear. METHODS: This was a single-center retrospective review conducted on 500 patients with PE. After applying the inclusion and exclusion criteria, 386 patients diagnosed with PE were enrolled in our study. These patients were then categorized into the PI group (n=64) and the non-PI group (n=322). A comparison was conducted between the two groups regarding the clinical characteristics...
November 30, 2023: Journal of Thoracic Disease
https://read.qxmd.com/read/37712377/pulmonary-vasculitis-in-beh%C3%A3-et-s-disease-reference-atlas-computed-tomography-pulmonary-angiography-ctpa-findings-and-risk-assessment-management-proposal
#11
JOURNAL ARTICLE
Yasser Emad, Yasser Ragab, Diletta Cozzi, Ossama Ibrahim, Walaa Abdelrahman, Mabrouk Abdelali, Melek Kechida, Manal Hassanin, Samar Tharwat, Shaimaa Salah, Nashwa Elshaarawy, Faten Frikha, Sara Hassanein, Pablo Young, Sonia Pankl, Bhupen Barman, Alaa Abou-Zeid, Johannes Rasker
BACKGROUND AND AIM:  Pulmonary artery aneurysms (PAAs) are the most well-defined type of pulmonary vascular complication in Behçet's disease (BD).The aim of this study is to analyze which CT pulmonary angiography (CTPA) signs are associated with serious morbidity and mortality. METHODS: The study included 42 BD patients with pulmonary vascular complications. All patients' medical records were reviewed retrospectively in terms of demographics, disease characteristics, laboratory investigations, pulmonary manifestations, arterial and/or venous thrombosis and CTPA vascular and parenchymal findings...
September 13, 2023: Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG
https://read.qxmd.com/read/37804848/comparison-of-international-guideline-recommendations-for-the-diagnosis-of-pulmonary-embolism
#12
REVIEW
Casper Falster, Maja Hellfritzsch, Thomas Agerbo Gaist, Mikkel Brabrand, Rahul Bhatnagar, Mads Nybo, Niels Holmark Andersen, Gro Egholm
Pulmonary embolism is one of the leading causes of death due to cardiovascular disease. Timely diagnosis is crucial, but challenging, as the clinical presentation of pulmonary embolism is unspecific and easily mistaken for other common medical emergencies. Clinical prediction rules and D-dimer measurement allow stratification of patients into groups of expected prevalence and are key elements in adequate selection of patients for diagnostic imaging; however, the strengths and weaknesses of the multiple proposed prediction rules, when to measure D-dimer, and which cutoff to apply might be elusive to a significant proportion of physicians...
November 2023: Lancet Haematology
https://read.qxmd.com/read/37673431/venous-thromboembolism-with-use-of-hormonal-contraception-and-non-steroidal-anti-inflammatory-drugs-nationwide-cohort-study
#13
JOURNAL ARTICLE
Amani Meaidi, Annamaria Mascolo, Maurizio Sessa, Anne Pernille Toft-Petersen, Regitze Skals, Thomas Alexander Gerds, Charlotte Wessel Skovlund, Lina Steinrud Morch, Francesco Rossi, Annalisa Capuano, Oejvind Lidegaard, Christian Torp-Pedersen
OBJECTIVE: To study the influence of concomitant use of hormonal contraception and non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of venous thromboembolism. DESIGN: Nationwide cohort study. SETTING: Denmark through national registries. PARTICIPANTS: All 15-49 year old women living in Denmark between 1996 and 2017 with no medical history of any venous or arterial thrombotic event, cancer, thrombophilia, hysterectomy, bilateral oophorectomy, sterilisation, or infertility treatment (n=2 029 065)...
September 6, 2023: BMJ: British Medical Journal
https://read.qxmd.com/read/37611622/safety-and-efficacy-of-therapeutic-anticoagulation-with-subcutaneous-unfractionated-heparin-in-patients-with-renal-failure
#14
JOURNAL ARTICLE
Giulia Simini, Frances Akor, Richard Szydlo, Michael Laffan, Deepa R J Arachchillage
No abstract text is available yet for this article.
August 23, 2023: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/37638968/edoxaban-for-12-months-versus-3-months-in-patients-with-cancer-with-isolated-distal-deep-vein-thrombosis-onco-dvt-study-an-open-label-multicenter-randomized-clinical-trial
#15
RANDOMIZED CONTROLLED TRIAL
Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Takuya Oyakawa, Michihisa Umetsu, Daijirou Akamatsu, Yuji Nishimoto, Yukihito Sato, Takuma Takada, Kentaro Jujo, Yuichiro Minami, Yoshito Ogihara, Kaoru Dohi, Masashi Fujita, Tatsuya Nishikawa, Nobutaka Ikeda, Go Hashimoto, Kazunori Otsui, Kenta Mori, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Yusuke Yoshikawa, Takeshi Kimura
BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned patients with cancer with isolated distal deep vein thrombosis, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment...
November 21, 2023: Circulation
https://read.qxmd.com/read/37278934/direct-oral-anticoagulants-for-cancer-associated-venous-thromboembolism
#16
REVIEW
Marta Masini, Matteo Toma, Paolo Spallarossa, Italo Porto, Pietro Ameri
PURPOSE OF REVIEW: To present the randomized controlled trial (RCT) evidence and highlight the areas of uncertainty regarding direct oral anticoagulants (DOAC) for cancer-associated venous thromboembolism (CAT). RECENT FINDINGS: In the last years, four RCTs have shown that rivaroxaban, edoxaban, and apixaban are at least as effective as low-molecular-weight heparin (LMWH) for the treatment of both incidental and symptomatic CAT. On the other hand, these drugs increase the risk of major gastrointestinal bleeding in patients with cancer at this site...
June 6, 2023: Current Oncology Reports
https://read.qxmd.com/read/36940716/laboratory-evaluation-of-antithrombin-protein-c-and-protein-s
#17
JOURNAL ARTICLE
Richard A Marlar
Thrombophilia is a complex disease process, clinically manifesting in various forms of venous thromboembolism. Although both genetic and acquired (or environmental) risks factors have been reported, the presence of a genetic defect (antithrombin [AT], protein C [PC], protein S [PS]) is considered three of the major contributing factors of thrombophilia. The presence of each of these risk factors can be established by clinical laboratory analysis; however, the clinical provider and laboratory personnel must understand the testing limitations and shortcomings associated with the assays for these factors to be able to ensure an accurate diagnosis...
September 2023: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/37201536/prevention-of-venous-thromboembolism-in-medical-patients-with-thrombocytopenia-or-with-platelet-dysfunction-the-last-10-years
#18
JOURNAL ARTICLE
Antonella Tufano, Benjamin Brenner
Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially in those with multiple VTE risk factors...
May 18, 2023: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/37455352/high-risk-pulmonary-embolism-management-for-the-intensivist
#19
REVIEW
Akhil Khosla, Yiyu Zhao, Hamid Mojibian, Jeffrey Pollak, Inderjit Singh
High-risk pulmonary embolism (PE) also known as massive PE carries a high rate of morbidity and mortality. The incidence of high-risk PE continues to increase, yet the outcomes of high-risk PE continue to remain poor. Patients with high-risk PE are often critically ill, with complex underlying physiology, and treatment for the high-risk PE patient almost always requires care and management from an intensivist. Treatment options for high-risk PE continue to evolve rapidly with multiple options for definitive reperfusion therapy and supportive care...
December 2023: Journal of Intensive Care Medicine
https://read.qxmd.com/read/37439553/management-of-patients-on-antithrombotic-therapy-with-severe-infections-a-joint-clinical-consensus-statement-of-the-esc-working-group-on-thrombosis-the-esc-working-group-on-atherosclerosis-and-vascular-biology-and-the-international-society-on-thrombosis-and
#20
JOURNAL ARTICLE
Bruna Gigante, Jerrold H Levy, Eric van Gorp, Alessandro Bartoloni, Marie-Luce Bochaton-Piallat, Magnus Bäck, Hugo Ten Cate, Christina Christersson, José Luis Ferreiro, Tobias Geisler, Esther Lutgens, Sam Schulman, Robert F Storey, Jecko Thachil, Gemma Vilahur, Patricia C Liaw, Bianca Rocca
Patients with severe infections and a pre-existing indication for antithrombotic therapy, i.e. antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical counselling among coagulation, infectious disease, and cardiology specialists, due to sepsis-induced coagulopathy that frequently occurs. Bacterial and viral pathogens constitute an increasing threat to global public health, especially for patients with ongoing antithrombotic treatment who have a high risk of thrombotic recurrences and high susceptibility to severe infections with increased morbidity and mortality...
July 13, 2023: European Heart Journal
label_collection
label_collection
5849
1
2
2023-07-24 05:47:59
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.